CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
PARSIPPANY, N.J., Nov. 06, 2026 (ZM NEWSWIRE) — CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 12, 2026, and will host a corporate update conference call at 8:30 a.m. Eastern Standard Time.
| Thursday, November 12th at 8:30 a.m. EST | |
| Domestic: | 1-844-676-2922 |
| International: | 1-412-634-6840 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional settings of care in the US and has field-based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
Publication Partner: ZM Newswire – Powered By Zeest Media
This press release is provided by the issuer. The statements and opinions expressed are those of the author and do not necessarily reflect the views of Zeest Media.
© 2026 Zeest Media. All rights reserved.
